BC Week In Review | Aug 10, 2015
Clinical News

DP-b99: Phase II final data

Final data from a double-blind, European Phase II trial in 10 patients with acute, high-risk pancreatitis showed that twice-daily IV DP-b99 for 2 days was well tolerated. Additionally, a non-pre-specified analysis of inflammatory markers showed...
BC Week In Review | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18 plus...
BC Week In Review | Jun 30, 2014
Clinical News

DP-VPA regulatory update

D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA plans to begin a Phase I trial in...
BC Week In Review | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

Interim data from the first cohort of patients with acute ischemic stroke in a double-blind, placebo-controlled, Ukrainian Phase IIa trial showed that a single dose of 0.18 mg/kg THR-18 in combination with tissue plasminogen activator...
BC Week In Review | Dec 9, 2013
Clinical News

DP-b99: Phase II started

D-Pharm began a double-blind, placebo-controlled, European Phase II trial to evaluate twice-daily IV DP-b99 for 2 days in 30 patients with high-risk acute pancreatitis. Last year, the company discontinued development of the compound to treat...
BC Week In Review | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

On Oct. 22, D-Pharm said it will begin a double-blind, placebo-controlled, Ukrainian Phase IIa trial to evaluate 3 single ascending-doses of THR-18 in combination with tissue plasminogen activator (tPA) in about 30 patients with acute...
BC Week In Review | Oct 21, 2013
Clinical News

DP-b99: Phase II start

This quarter, D-Pharm will begin a double-blind, placebo-controlled Phase II trial to evaluate DP-b99 in patients with acute pancreatitis. Last year, the company discontinued development of the compound to treat ischemic stroke due to lack...
BC Week In Review | May 28, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
BC Extra | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...
Items per page:
1 - 10 of 96
BC Week In Review | Aug 10, 2015
Clinical News

DP-b99: Phase II final data

Final data from a double-blind, European Phase II trial in 10 patients with acute, high-risk pancreatitis showed that twice-daily IV DP-b99 for 2 days was well tolerated. Additionally, a non-pre-specified analysis of inflammatory markers showed...
BC Week In Review | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18 plus...
BC Week In Review | Jun 30, 2014
Clinical News

DP-VPA regulatory update

D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA plans to begin a Phase I trial in...
BC Week In Review | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

Interim data from the first cohort of patients with acute ischemic stroke in a double-blind, placebo-controlled, Ukrainian Phase IIa trial showed that a single dose of 0.18 mg/kg THR-18 in combination with tissue plasminogen activator...
BC Week In Review | Dec 9, 2013
Clinical News

DP-b99: Phase II started

D-Pharm began a double-blind, placebo-controlled, European Phase II trial to evaluate twice-daily IV DP-b99 for 2 days in 30 patients with high-risk acute pancreatitis. Last year, the company discontinued development of the compound to treat...
BC Week In Review | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

On Oct. 22, D-Pharm said it will begin a double-blind, placebo-controlled, Ukrainian Phase IIa trial to evaluate 3 single ascending-doses of THR-18 in combination with tissue plasminogen activator (tPA) in about 30 patients with acute...
BC Week In Review | Oct 21, 2013
Clinical News

DP-b99: Phase II start

This quarter, D-Pharm will begin a double-blind, placebo-controlled Phase II trial to evaluate DP-b99 in patients with acute pancreatitis. Last year, the company discontinued development of the compound to treat ischemic stroke due to lack...
BC Week In Review | May 28, 2012
Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
BC Extra | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...
Items per page:
1 - 10 of 96